Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franco Muggia

Showing results (1-10 of 95) with videos related to

Pageof 10
Sort By:
Cancer Investigation|January 23, 2004
Doxorubicin for metastatic breast cancer: time for a change?Franco Muggia
Gynecologic Oncology|November 4, 2008
Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancerFranco Muggia
Cancer Investigation|August 29, 2002
Stable disease in mesothelioma: a therapeutic achievement?Franco Muggia
Hematology/Oncology Clinics of North America|April 24, 2012
Clinical drug development in 2012Franco Muggia
Gynecologic Oncology|September 8, 2006
More on intraperitoneal therapyFranco Muggia
Drugs|May 9, 2012
Bevacizumab in ovarian cancer: unanswered questionsFranco Muggia
The Oncologist|October 24, 2020
Weekly Carboplatin and Paclitaxel for Ovarian Cancer: The "Finer Points"Franco Muggia
Cancer Investigation|March 23, 2005
Ezra Greenspan: a trailblazer in combination chemotherapyFranco Muggia
The Oncologist|March 15, 2013
Squamous cell carcinomas of the tongue and oral cavity as secondary malignancies: what factors are implicated?Franco Muggia
Oncology (Williston Park, N.Y.)|September 20, 2015
Clinical Trials of Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: Unanswered QuestionsMaryann Kwa, Franco Muggia
Pageof 10

Showing results (1-10 of 95) with videos related to

Sort By:
Pageof 10
Cancer Investigation|January 23, 2004
Doxorubicin for metastatic breast cancer: time for a change?Franco Muggia
Gynecologic Oncology|November 4, 2008
Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancerFranco Muggia
Cancer Investigation|August 29, 2002
Stable disease in mesothelioma: a therapeutic achievement?Franco Muggia
Hematology/Oncology Clinics of North America|April 24, 2012
Clinical drug development in 2012Franco Muggia
Gynecologic Oncology|September 8, 2006
More on intraperitoneal therapyFranco Muggia
Drugs|May 9, 2012
Bevacizumab in ovarian cancer: unanswered questionsFranco Muggia
The Oncologist|October 24, 2020
Weekly Carboplatin and Paclitaxel for Ovarian Cancer: The "Finer Points"Franco Muggia
Cancer Investigation|March 23, 2005
Ezra Greenspan: a trailblazer in combination chemotherapyFranco Muggia
The Oncologist|March 15, 2013
Squamous cell carcinomas of the tongue and oral cavity as secondary malignancies: what factors are implicated?Franco Muggia
Oncology (Williston Park, N.Y.)|September 20, 2015
Clinical Trials of Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: Unanswered QuestionsMaryann Kwa, Franco Muggia
Pageof 10